Insilico Medicine vs Amazon Q Business

Enterprise and institutional licensing for pharmaceutical partners. No public access. Public company listed on NASDAQ.

Lite $3/user/month (basic). Business $20/user/month (full features including document creation). 30-day free trial.

Drug discovery research data processed under enterprise partnership data handling agreements. Review applicable regulatory requirements for clinical programme data.

Data processed within AWS infrastructure. Customer data not used to train foundation models. IAM access controls ensure employees access only authorised content in responses.

• ✓INS018_055 in Phase 2 clinical trials is the most advanced AI-designed drug in human trials
• ✓Chemistry42 generative AI designs novel molecules rather than only screening existing libraries
• ✓First company to advance a fully AI-designed drug candidate to clinical trials
• ✓NASDAQ listing (ILAB) provides financial transparency for pharma partnership assessment

• ✓40+ data source connectors cover most enterprise data systems without custom integration
• ✓IAM access controls ensure employees only see data they are authorised to access
• ✓Q Apps no-code application builder for non-technical employees
• ✓$3/user/month Lite tier is affordable for broad internal deployment

• ✕Drug discovery is inherently long-cycle — AI acceleration is still measured in years, not weeks
• ✕Clinical success probability remains uncertain — most drug candidates fail in clinical trials
• ✕Enterprise partnership model means capabilities are not broadly accessible as a self-serve platform

• ✕Enterprise knowledge quality depends on the quality and organisation of underlying data sources
• ✕Less mature than Microsoft's M365 Copilot ecosystem for Microsoft-centric organisations
• ✕No-code Q Apps are simple — complex AI workflows require Q Business API or Lambda